Fintel reports that on May 30, 2024, Goldman Sachs initiated coverage of Edwards Lifesciences (NYSE:EW) with a Buy recommendation.
Analyst Price Forecast Suggests 12.71% Upside
As of May 22, 2024, the average one-year price target for Edwards Lifesciences is 98.09. The forecasts range from a low of 73.73 to a high of $110.25. The average price target represents an increase of 12.71% from its latest reported closing price of 87.03.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Edwards Lifesciences is 6,579MM, an increase of 7.09%. The projected annual non-GAAP EPS is 2.94.
What is the Fund Sentiment?
There are 2,111 funds or institutions reporting positions in Edwards Lifesciences. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to EW is 0.28%, an increase of 0.31%. Total shares owned by institutions decreased in the last three months by 0.49% to 537,353K shares. 
The put/call ratio of EW is 0.70, indicating a bullish outlook.
What are Other Shareholders Doing?
Bank of New York Mellon holds 18,973K shares representing 3.15% ownership of the company. In its prior filing, the firm reported owning 17,328K shares , representing an increase of 8.67%. The firm decreased its portfolio allocation in EW by 85.65% over the last quarter.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 18,937K shares representing 3.14% ownership of the company. In its prior filing, the firm reported owning 19,054K shares , representing a decrease of 0.62%. The firm increased its portfolio allocation in EW by 13.56% over the last quarter.
Brown Advisory holds 16,636K shares representing 2.76% ownership of the company. In its prior filing, the firm reported owning 18,181K shares , representing a decrease of 9.29%. The firm decreased its portfolio allocation in EW by 46.15% over the last quarter.
Alliancebernstein holds 16,406K shares representing 2.72% ownership of the company. In its prior filing, the firm reported owning 19,089K shares , representing a decrease of 16.35%. The firm decreased its portfolio allocation in EW by 14.97% over the last quarter.
Wellington Management Group Llp holds 15,550K shares representing 2.58% ownership of the company. In its prior filing, the firm reported owning 16,828K shares , representing a decrease of 8.22%. The firm decreased its portfolio allocation in EW by 84.36% over the last quarter.
Edwards Lifesciences Background Information
(This description is provided by the company.)
Edwards Lifesciences is the global leader of patient-focused innovations for structural heart disease and critical care monitoring. Edwards Lifesciences is driven by a passion for patients, dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
